Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocurcumin in psychotic methamphetamine users
IRCT20240208060938N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of nanocurcumin in Schizophrenia Spectrum Disorders (SSD), sponsored by Kashan University of Medical Sciences. Started Apr 2024; status: completed.
02
Drugs
nanocurcumin
03
Conditions
Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on IRCT20240208060938N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240208060938N1.